Bank of America
KPTI icon

Bank of America’s Karyopharm Therapeutics KPTI Stock Holding History

Bank of America’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Sell
19,472
-28,616
-60% -$218K ﹤0.01% 5506
2025
Q4 		$354K Buy
48,088
+47,994
+51,057% +$294K ﹤0.01% 5089
2025
Q3 		$615 Sell
94
-168,440
-100% -$906K ﹤0.01% 7557
2025
Q2 		$726K Buy
168,534
+35,626
+27% +$175K ﹤0.01% 5497
2025
Q1 		$497K Buy
132,908
+122,127
+1,133% +$1.04M ﹤0.01% 5653
2024
Q4 		$109K Sell
10,781
-4,482
-29% -$54.2K ﹤0.01% 6353
2024
Q3 		$190K Sell
15,263
-4,649
-23% -$57.8K ﹤0.01% 6018
2024
Q2 		$259K Buy
19,912
+9,384
+89% +$155K ﹤0.01% 5745
2024
Q1 		$238K Sell
10,528
-9,902
-48% -$174K ﹤0.01% 5799
2023
Q4 		$265K Sell
20,430
-3,078
-13% -$41.5K ﹤0.01% 5917
2023
Q3 		$473K Buy
23,508
+1,079
+5% +$24.2K ﹤0.01% 5352
2023
Q2 		$602K Sell
22,429
-121,423
-84% -$5.23M ﹤0.01% 5150
2023
Q1 		$8.39M Buy
143,852
+43,108
+43% +$2.13M ﹤0.01% 3003
2022
Q4 		$5.14M Buy
100,744
+51,953
+106% +$3.6M ﹤0.01% 3358
2022
Q3 		$4M Buy
48,791
+16,830
+53% +$1.26M ﹤0.01% 3571
2022
Q2 		$2.16M Sell
31,961
-42,454
-57% -$3.89M ﹤0.01% 4242
2022
Q1 		$8.23M Buy
74,415
+57,424
+338% +$7.16M ﹤0.01% 3054
2021
Q4 		$1.64M Buy
16,991
+1,263
+8% +$126K ﹤0.01% 4759
2021
Q3 		$1.37M Buy
15,728
+33
+0.2% +$3.43K ﹤0.01% 4783
2021
Q2 		$2.43M Buy
15,695
+676
+5% +$98.1K ﹤0.01% 4166
2021
Q1 		$2.37M Buy
15,019
+3,905
+35% +$823K ﹤0.01% 4113
2020
Q4 		$2.58M Sell
11,114
-874
-7% -$203K ﹤0.01% 3721
2020
Q3 		$2.63M Buy
11,988
+2,043
+21% +$500K ﹤0.01% 3465
2020
Q2 		$2.83M Buy
9,945
+3,325
+50% +$983K ﹤0.01% 3349
2020
Q1 		$1.91M Buy
6,620
+1,012
+18% +$279K ﹤0.01% 3517
2019
Q4 		$1.61M Buy
5,608
+1,602
+40% +$348K ﹤0.01% 4176
2019
Q3 		$579K Buy
4,006
+377
+10% +$51.1K ﹤0.01% 4972
2019
Q2 		$326K Sell
3,629
-1,166
-24% -$93.6K ﹤0.01% 5352
2019
Q1 		$421K Buy
4,795
+833
+21% +$92.3K ﹤0.01% 5118
2018
Q4 		$557K Sell
3,962
-754
-16% -$127K ﹤0.01% 4864
2018
Q3 		$1.21M Sell
4,716
-381
-7% -$105K ﹤0.01% 4363
2018
Q2 		$1.3M Buy
5,097
+2,104
+70% +$520K ﹤0.01% 4302
2018
Q1 		$602K Buy
2,993
+156
+5% +$31.1K ﹤0.01% 4706
2017
Q4 		$408K Sell
2,837
-256
-8% -$41.1K ﹤0.01% 5066
2017
Q3 		$510K Buy
3,093
+120
+4% +$17.2K ﹤0.01% 4936
2017
Q2 		$403K Sell
2,973
-102
-3% -$15.1K ﹤0.01% 5007
2017
Q1 		$592K Buy
3,075
+20
+0.7% +$3.21K ﹤0.01% 4781
2016
Q4 		$431K Buy
3,055
+1
+0% +$135 ﹤0.01% 4900
2016
Q3 		$446K Sell
3,054
-766
-20% -$92.1K ﹤0.01% 4705
2016
Q2 		$385K Sell
3,820
-25
-0.7% -$3.25K ﹤0.01% 4824
2016
Q1 		$514K Sell
3,845
-1,021
-21% -$113K ﹤0.01% 4581
2015
Q4 		$967K Sell
4,866
-253
-5% -$54.8K ﹤0.01% 4389
2015
Q3 		$809K Sell
5,119
-3,238
-39% -$866K ﹤0.01% 4487
2015
Q2 		$3.41M Sell
8,357
-1,562
-16% -$675K ﹤0.01% 2942
2015
Q1 		$4.55M Buy
9,919
+7,335
+284% +$3.16M ﹤0.01% 2554
2014
Q4 		$1.45M Buy
2,584
+1,469
+132% +$834K ﹤0.01% 3704
2014
Q3 		$584K Buy
1,115
+53
+5% +$29.9K ﹤0.01% 4443
2014
Q2 		$741K Sell
1,062
-534
-33% -$249K ﹤0.01% 4249
2014
Q1 		$739K Buy
1,596
+1,519
+1,973% +$770K ﹤0.01% 4215
2013
Q4 		$26K Buy
+77
New +$21.3K ﹤0.01% 6913

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Bank of America's KPTI Position: Q1 2026 in Review

Bank of America reduced its Karyopharm Therapeutics (KPTI) stake by 60% in Q1 2026, selling an estimated $218K and leaving 19,472 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #5506.

Bank of America first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $8.39M in Q1 2023. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Bank of America held 19,472 shares of Karyopharm Therapeutics worth $108K as of Q1 2026.
  • Bank of America sold 28,616 Karyopharm Therapeutics shares in Q1 2026, an estimated $218K.
  • Karyopharm Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5506 holding.
  • Bank of America first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • Bank of America's Karyopharm Therapeutics position peaked at $8.39M in Q1 2023.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.